Caveolin‑1 is a membrane-associated protein expressed in many cell types that plays a key role in modulating inflammatory ...

A trio of studies from the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting show the potential of several emerging treatments for dry eye disease.

Spinogenix, Inc.,  a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, will present this ...

Safety signals with faricimab in routine practice, including intraocular inflammation and endophthalmitis, aligned with prior ...

OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that its abstract has been ...

New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DMEKey data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...